The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
This clinical trial will evaluate whether treatment with ridaforolimus, dalotuzumab, or ridforolimus/dalotuzumab combination therapy reduces Growth Factor Signature (GFS) Score among participants with breast cancer.
Breast Cancer
DRUG: Ridaforolimus + Dalotuzumab|DRUG: Ridaforolimus|DRUG: Dalotuzumab
The population mean change from baseline in GFS (Growth Factor Signature) score, Baseline and Day 15
The population mean change from baseline in Ki67 among participants receiving ridaforolimus/dalotuzumab combination therapy, Baseline and Day 15|The correlation between change in Ki67 expression and change in GFS after two weeks of treatment with ridaforolimus/dalotuzumab (MK-8669/MK-0646) combination therapy, ridaforolimus (MK-8669) monotherapy and/or dalotuzumab (MK-0646) monotherapy, Baseline and Day 15
This clinical trial will evaluate whether treatment with ridaforolimus, dalotuzumab, or ridforolimus/dalotuzumab combination therapy reduces Growth Factor Signature (GFS) Score among participants with breast cancer.